Developability profiles for monoclonal antibodies require stability data to inform on rational design and selection of therapeutic constructs that are most likely to succeed in the clinic.
Prometheus Panta – a tool for multi-parameter stability characterization of biologics – delivers high-quality data on your constructs with reliable, high-resolution data on many stability parameters with low sample consumption.
In this webinar, learn more about the technology inside and how the discovery group at Merck & Co. used Prometheus Panta to assess multiple developability characteristics of their mAb therapeutics, and gained deeper insight into the quality attributes of their candidates.
You’ll learn:
- What technologies are in the Prometheus Panta instrument, and what they tell you about your protein-based therapeutics
- How the Protein Science team from Merck & Co. used Prometheus Panta to rank and characterize engineered antibodies
- Why high-resolution, trustworthy data is so critical to a successful developability work
Related resources:
Learn more about the work of the Protein Science Group at Merck & Co. in this application note
Explore Prometheus Panta in a short 10 min video walthrough.
